In vivo systemic component analysis allows scientists to investigate cellular behavior in the most reliable way. This is particularly true when the activity under scrutiny is heavily influenced by cell-cell interactions (both contact- and non-contact-dependent), as in the nervous system, where membrane voltage changes drive the communication among excitable cells. The comprehension of the information encoded by these electrical signals is the key to understanding the way the nervous system works in both physiological and disease states.
In order to study cell electrical properties in the most non-invasive physiological conditions, several genetically encoded voltage indicators have been recently developed1. As opposed to the previous generations of optical voltage sensors (mainly voltage-sensitive dyes)2, GEVIs allow for in vivo analyses of the intact neural system, and their expression can be limited to specific cell types or populations.
The zebrafish embryo is the in vivo "substrate" of choice to take advantage of the great potential attributed to GEVIs. In fact, thanks to its optical clarity and its simplified yet evolutionarily conserved nervous system, the zebrafish model allows for the straightforward identification and manipulation of every cellular component in a network. Indeed, the employment of the FRET-based GEVI Mermaid3 led to the identification of pre-symptomatic alterations in spinal motor neuron behavior in a zebrafish model of amyotrophic lateral sclerosis (ALS)4.
The following in vivo protocol describes how to monitor the electrical properties of spinal motor neurons in intact zebrafish embryos expressing Mermaid in a neuronal-specific manner. Moreover, it demonstrates how pharmacologically induced changes in such electrical properties can be associated with alterations in the frequency of embryonic spontaneous coilings, the stereotypic motor activity that characterizes the movement behavior of the zebrafish at very early stages of development.